Efficient uptake of recombinant α-galactosidase a produced with a gene-manipulated yeast by fabry mice kidneys

Takahiro Tsukimura, Ikuo Kawashima, Tadayasu Togawa, Takashi Kodama, Toshihiro Suzuki, Toru Watanabe, Yasunori Chiba, Yoshifumi Jigami, Tomoko Fukushige, Takuro Kanekura, Hitoshi Sakuraba

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

To economically produce recombinant human α-galactosidase A (GLA) with a cell culture system that does not require bovine serum, we chose methylotrophic yeast cells with the OCH1gene, which encodes α-1,6-mannosyltransferase, deleted and over-expressing the Mnn4p (MNN4) gene, which encodes a positive regulator of mannosylphosphate transferase, as a host cell line. The enzyme (yr-hGLA) produced with the gene-manipulated yeast cells has almost the same enzymological parameters as those of the recombinant human GLA produced with cultured human fibroblasts (agalsidase alfa), which is currently used for enzyme replacement therapy for Fabry disease. However, the basic structures of their sugar chains are quite different. yr-hGLA has a high content of phosphorylated N-glycans and is well incorporated into the kidneys, the main target organ in Fabry disease, where it cleaves the accumulated glycosphingolipids. A glycoprotein production system involving this gene-manipulated yeast cell line will be useful for the development of a new enzyme replacement therapy for Fabry disease.

Original languageEnglish
Pages (from-to)76-82
Number of pages7
JournalMolecular Medicine
Volume18
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Efficient uptake of recombinant α-galactosidase a produced with a gene-manipulated yeast by fabry mice kidneys'. Together they form a unique fingerprint.

Cite this